
usd may pm et
summari engag discoveri develop commerci treatment
infect respiratori disord cardiovascular condit cancer
price-to-earnings oper ep
risk assess reflect gilead abil increas
domin hiv market share off-set slow
hepat market see opportun oncolog
emerg potenti long-term growth driver
past perform indic futur perform reli upon
analysi prepar equiti analyst
may pm stock trade
expect gild revenu
roughli flat yoy billion vs billion
follow year precipit revenu
declin due well-known shrink
hcv market gild sale stabil
growth new product yescarta
cancer biktarvi hiv off-set smaller declin
hcv busi
expect gild hiv franchis continu
grow expect
gener competit begin erod gild
hiv leadership sale hiv
antivir rose billion driven
tenofovir alafenamid taf base drug
biktarvi expect sale growth
led biktarvi hiv treatment
descovi hiv pre-exposur prophylaxi
sinc last year pursu
extern opportun bolster pipelin
howev asset deal
still unproven far contribut
meaning profit juli
enter collabor agreement
galapago glpg billion april
complet billion
acquisit forti seven
find share trade
ep fair valu
think excit around remdesivir
first fda-approv treatment
push share much higher level
warrant remdesivir unlik view
signific last sourc profit
given low-margin profil likelihood
futur vaccin elimin need
treatment excit
remdesivir fade investor focu like
return base busi still lack
clear opportun long-term growth
near term disrupt
anticip weak descovi switch
difficulti anticip launch
filgotinib crowd rheumatoid arthriti
market rapidli switch patient descovi
truvada prep critic
 patent expir truvada
risk recommend target price
includ weaker-than-expect sale key
product pipelin disappoint poor
target price reflect forward price-to-earnings
ep
jul ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview research-bas biopharmaceut compani
discov develop commerci innov medicin area unmet medic need gild
primari area focu includ hiv/aid liver diseas hematology/oncolog
inflammation/respiratori diseas oper countri world-wide end
gild research develop pipelin includ activ clinic studi
phase clinic trial addit complet collabor partnership strateg
invest earli market product across primari area
focu
total product sale billion sale come gild
largest franchis product sale hiv franchis gener billion sale gild hiv
franchis matur face increas competit work defend franchis
launch newer effect therapi success launch biktarvi
once-daili singl tablet tripl regimen approv fda februari european
commiss june
gild hiv franchis follow compani chronic hepat viru hcv franchis achiev
billion sale billion sale gild hcv franchis
declin patient becom cure
outsid gild key therapeut franchis hiv hcv see near-term potenti commerci
product yescarta non-hodgkin lymphoma clinic candid selonsertib treatment
nash filgotinib treatment rheumatoid arthriti
competit environ oper highli competit environ compani face
signific competit global pharmaceut biotechnolog compani special
pharmaceut firm gener drug manufactur gild product compet commerci
avail product base primarili efficaci safeti toler accept doctor eas patient
complianc eas use price insur reimburs coverag distribut market
gild product matur privat insur govern payer often reduc amount
reimburs patient increas pressur reduc price new brand gener
product introduc major market gild abil maintain price market share may
major develop juli enter collabor agreement galapago
glpg up-front payment equiti invest return gain access glpg
drug discoveri platform drug portfolio contain six molecul clinic trial
juli presid ceo john milligan announc would step end year new
ceo daniel oday took march prior oday serv ceo roch
pharmaceut appoint day senior manag line-up experienc
signific amount chang
octob acquir kite pharma billion expand presenc cell therapi
field month kite gene-therapi yescarta becam first fda-approv chimer antigen
receptor cell therapi yescarta treat adult non-hodgkin lymphoma
chemotherapi fail second fda-approv gene therapi took
million charg relat discontinu kite anti-bcma program treatment
multipl myeloma acquir kite pharma
financi trend gild revenu declin year-over-year billion primarili due
declin hcv franchis expect declin hcv franchis deceler next
year adjust ep free cash flow
billion billion march net cash posit
execut vice-president corpor
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
bullish sinc april technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
spite global recess
concern posit outlook
histor defens sub-industri
expect see ramp-up new drug sale
continu develop mani new
innov therapi declin
preval patent expir
partli due govern shutdown
earli fda approv new drug
declin
fda approv shatter previou
record sinc novel approv set
new drug typic take least
year reach peak sale level mean
overal biotech industri like see
promis sale growth next year
addit think mani drug
either newli approv late-stag
clinic trial repres major advanc
treatment technolog gene therapi
zolgensma believ cure spinal
muscular atrophi one inject
expect impact larg
immateri suppli demand side
thing biotech firm although
firm industri could benefit
develop treatment vaccin sever
biotech firm work develop vaccin
treatment includ regeneron gilead
coverag warn investor
effect treatment vaccin often take
year develop difficult
determin whether treatment effect
prior gather signific amount
clinic data also expect substanti
price pressur treatment
commerci given urgent
widespread natur pandem
mean upsid success
treatment like minor
also impact biotech firm
clinic trial delay think
delay mostli immateri
near-term revenu long-term outlook
although deal count biopharmaceut
 lower
past decad total deal valu transact
billion largest amount
sinc accord evaluatepharma
total deal valu driven coupl
mega-d bristol-mey squibb
acquisit celgen
acquisit botox manufactur allergan
decemb biotech industri debt
level remain low rel histor level
rel industri addit
late march sub-industri valuat
sub-industri out-performance
lead us believ like
continu favor
environ biopharma
investor interest
biotechnolog stock mute high
drug price intens scrutini
 polit apparatu despit polit
littl happen neg impact
profit biotech firm dont
expect drug legisl come back
focu novemb
year-to-d march
biotechnolog index declin vs
declin composit
biotech index increas
rise valu
base index
five-year market price perform may
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
inventori total million write-down mostli relat weak long-term
demand expect hcv product provid
weaker-than-expect guidanc lower ep
initi ep product sale
billion yoy billion strength hiv product sale led biktarvi
off-set declin hcv sale weaker-than-expect yescarta sale
topic novel coronaviru even success develop
treatment highli uncertain dont believ would fundament
chang long-term outlook also note chang
non-gaap present start longer exclud stock-bas
et cfra reiter hold opinion share inc
lower target price base
multipl vs three-year rang
ep estim ep vs
consensu rais ep revenu
billion million consensu expect overal
quarter result unev mostli line expect hiv
product sale expand billion yoy billion driven
world-wide biktarvi sale grew sequenti yoy
billion key focu continu pipelin capit
alloc appear lack combin clinic candid
could meaning acceler top- bottom-lin growth next
sever year manag team gone signific chang
recent might compani yet made move
materi bolster late-stag pipelin /kevin huang cfa
analyst research note compani news
et cfra keep sell opinion share inc
keep target price reflect
ep ep vs ahead expect
primarili top-lin beat driven custom stock
respons expect benefit revers later think
could also experi mild short-term weak hcv hiv
busi fewer patient access treatment cut ep estim
remdesivir could see fda approv soon treat
unlik signific last sourc profit
given low-margin profil likelihood futur vaccin elimin
need treatment excit remdesivir fade
investor focu like return base busi still lack clear
opportun growth near term anticip weak descovi
switch difficulti virtual launch filgotinib rheumatoid
pm et cfra maintain sell opinion share
today announc posit data niaid placebo-control
trial remdesivir treatment result phase simpl
trial evalu dose durat remdesivir niaid
trial met primari endpoint reduc patient recoveri time result
said trial present upcom niaid brief find
niaid trial result particularli encourag like lead
fda approv emerg use author remdesivir could help
significantli reduc burden health care system
improv patient recoveri time howev believ suppli
constrain lift price target share reflect
increas convict remdesivir role address
pandem yet continu believ hype around outweigh
potenti benefit share made clear remdesivir
access afford /kevin huang cfa
et cfra lower opinion share inc sell
hold yesterday stat news websit report
patient treat gild antivir drug remdesivir demonstr rapid
recoveri fever respiratori symptom trial
enrol peopl sever diseas die howev studi
control group limit conclus drawn trial factor
make difficult assess remdesivir viabil treat
includ two control trial china discontinu
unknown reason recent data publish nejm highlight
non-neglig side effect niaid sponsor trial posit data
readout expect late may would much convinc
remdesivir efficaci treat sever patient even
believ remdesivir would provid littl upsid
price would like low respons undu optim toward remdesivir
lower rate share sell /kevin huang cfa
et cfra keep hold opinion share inc
recent optim treatment driven signific
out-performance share compani work treatment
 warn investor effect treatment vaccin often take
year develop difficult determin whether
treatment effect prior gather signific amount
clinic data also expect substanti price pressur treatment
commerci given urgent widespread natur
pandem estim success treatment
would worth dollar per share /kevin huang
et cfra maintain hold opinion share inc
keep target price reflect
ep estim ep vs fell short
consensu expect inventori write-down slow-mov excess
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
